We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Insulin and Alzheimer Disease—Reply

Suzanne Craft, PhD
Arch Neurol. 2012;69(5):670-671. doi:10.1001/archneurol.2012.45.
Text Size: A A A
Published online


In reply

In their interesting commentary, Dandona and colleagues highlight several of the potential mechanisms through which insulin may modulate Alzheimer disease (AD) pathologic processes. Indeed, one of the attractive features of insulin as a therapeutic agent for AD is that it affects multiple pathways of direct relevance to AD pathophysiology. Numerous points of interaction between insulin and amyloid processing have been identified including modulation of amyloid-related gene expression in peripheral mononuclear blood cells as observed by Dandona et al, regulation of proteases and lipoproteins related to amyloid clearance, and protection against amyloid toxicity.1,2 Insulin-related effects on inflammation, tau phosphorylation, and vascular function are other pathways that may influence the expression of AD pathology.3 These findings, combined with growing evidence of reduced insulin availability or action in the central nervous system of patients with AD, provide a rationale for therapeutic approaches that target insulin delivery to the brain.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





May 1, 2012
Manav Batra, MBBS; Husam Ghanim, PhD; Paresh Dandona, BSc, MB, BS, DPhil, FRCP
Arch Neurol. 2012;69(5):670-671. doi:10.1001/archneurol.2012.42.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
PubMed Articles

Care at the Close of Life: Evidence and Experience
Alzheimer Disease: "It's OK, Mama, If You Want to Go, It's OK"

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Supplemental Content